Protection of ovarian function by GnRH agonists during chemotherapy: A meta-analysis

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1335-1340

  Sun, Xiaomei ^a   Dongol, Samina ^a   Jiang, Jie ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Chemotherapy; GnRH agonists; Meta analysis; Ovarian damage

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN;

ADOLESCENT; ADULT; AGONISTS; CHILD; FEMALE; HUMAN; META ANALYSIS; MIDDLE AGED; NEOPLASMS; OVARY; PHYSIOLOGY; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; NEOPLASMS; OVARY; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

EID: 84894457175     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2296     Document Type: Article

References (25)

1. Surveillance, Epidemiology and End Results (SEER) Web site: Available online:http://www.seer.cancer.govApril 2010, based on the November 2009 submission.
2. Beck-Peccoz P and Persani L: Premature ovarian failure. Orphanet J Rare Dis 1: 9, 2006.
3. Sonmezer M and Oktay K: Fertility preservation in female patients. Hum Reprod Update 10: 251-266, 2004.
4. Bokser L, Szende B and Schally AV: Protective effects of D-Trp6-luteinizing hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 61: 861-865, 1990. (Pubitemid 20196992)
5. Ataya K, Rao LV, Lawrence E and Kimmel R: Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depeletion in rhesus monkeys. Biol Reprod 52: 365-372, 1995.
6. Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17: 74-78, 2006. (Pubitemid 43033843)
7. Clowse ME, Behera MA, Anders CK, Copland S, et al: Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Women's Health 18: 311-319, 2009.
8. Yang B, Shi W, Yang J, Liu H, Zhao H, et al: Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials. Breast 22: 150-157, 2013.
9. Turner NH, Partridge A, Sanna G, Di Leo A and Biganzoli L: Utility of gonadotropin-releasing hormone agonists forfertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 24: 2224-2235, 2013.
10. Higgins JPT and Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cohran Collaboration (updated March 2011).
11. Badawy A, Elnashar A, El-Ashry M and Shahat M: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91: 694-697, 2009.
12. Munster PN, Moore AP, et al: Randomized trial using gonadotropin- releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30: 533-538, 2012.
13. Waxman JH, Ahmed R, Smith D, Wrigley PEM, et al: Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19: 159-162, 1987. (Pubitemid 17059373)
14. Loverro G, Guarini A, Di Naro E, et al: Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12: 141-147, 2007.
15. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306: 269-276, 2011.
16. Elgindy EA, El-Haieg DO, Khorshid OM, et al: Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121: 78-86, 2013.
17. Gerber B, von Minlkwitz G, Stehle H, Reimer T, et al: Effect of luteining hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer therapy: The GBG 37 ZORO study. J Clin Oncol 29: 2334-2341, 2011.
18. Gilani MM, Hasanzadeh M, Ghaemmaghami F, et al: Ovarian preservation with gonadotrop in releasing hormone analog during chemotherapy. Asia Pac J Clin Oncol 3: 79-83, 2007. (Pubitemid 46887755)
19. Blumenfeld Z: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 12: 1044-1054, 2007.
20. Goswami D and Conway GS: Premature ovarian failure. Hum Reprod Update 11: 391-410, 2005. (Pubitemid 40895467)
21. Ravdin PM, Fritz NF, Tormey DC and Jordan VC: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48: 1026-1029, 1989.
22. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP and Cameron DA: The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21: 2583-2592, 2006. (Pubitemid 44542149)
23. Sverrisdottir A, Nystedt M, Johansson H and Fornander T: Adjuvant goserelin and ovarian preservation in chemotherapy-treated patients with early breast cancer: resultsfrom a randomized trial. Breast Cancer Res Treat 117: 561-567, 2009.
24. Partridge A, Gelber S, Gerber RD and Castiglione-Certsch M: Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43: 1646-1653, 2007. (Pubitemid 47042368)
25. Te Velde ER and Pearson PL: The variability of female reproductive ageing. Hum Reprod Upadate 8: 141-154, 2002. (Pubitemid 34428965)